CL2014002955A1 - Antagonista anticuerpo que se une a st2l y métodos de uso - Google Patents

Antagonista anticuerpo que se une a st2l y métodos de uso

Info

Publication number: CL2014002955A1
Authority: CL; Chile
Prior art keywords: st2l; binds; methods; antagonist antibody; antagonist
Prior art date: 2012-04-30

Application number

CL2014002955A

Other languages

English (en)

Inventor

Mark Tornetta

John Wheeler

Natalie Fursov

Karen Duffy

Catherine Healy

Roberta Lamb

Ravi Malaviya

Michael Pratta

Jinquan Lou

Michael Naso

Leroy Hall

Sheng-Jiun Wu

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-30

Filing date

2014-10-30

Publication date

2015-01-16

2014-10-30 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2015-01-16 Publication of CL2014002955A1 publication Critical patent/CL2014002955A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Zoology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Catching Or Destruction (AREA)

CL2014002955A 2012-04-30 2014-10-30 Antagonista anticuerpo que se une a st2l y métodos de uso CL2014002955A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261640238P	2012-04-30	2012-04-30
US201261640407P	2012-04-30	2012-04-30
US13/798,204 US9090694B2 (en)	2012-04-30	2013-03-13	ST2L antibody antagonists

Publications (1)

Publication Number	Publication Date
CL2014002955A1 true CL2014002955A1 (es)	2015-01-16

Family

ID=49477497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002955A CL2014002955A1 (es)	2012-04-30	2014-10-30	Antagonista anticuerpo que se une a st2l y métodos de uso

Country Status (37)

Country	Link
US (4)	US9090694B2 (es)
EP (2)	EP3597219A1 (es)
JP (3)	JP6283354B2 (es)
KR (2)	KR102147140B1 (es)
CN (2)	CN107098973A (es)
AR (1)	AR090909A1 (es)
AU (2)	AU2013256645B2 (es)
BR (1)	BR112014027165A2 (es)
CA (1)	CA2871948C (es)
CL (1)	CL2014002955A1 (es)
CO (1)	CO7240389A2 (es)
CR (1)	CR20140488A (es)
CY (1)	CY1122308T1 (es)
DK (1)	DK2844292T3 (es)
EA (2)	EA031047B1 (es)
EC (1)	ECSP14025178A (es)
ES (1)	ES2755094T3 (es)
HR (1)	HRP20191884T1 (es)
HU (1)	HUE045864T2 (es)
IL (2)	IL235401B (es)
LT (1)	LT2844292T (es)
MX (2)	MX358134B (es)
MY (1)	MY166062A (es)
NI (1)	NI201400125A (es)
NZ (3)	NZ740221A (es)
PE (1)	PE20150641A1 (es)
PH (2)	PH12014502435A1 (es)
PL (1)	PL2844292T3 (es)
PT (1)	PT2844292T (es)
RS (1)	RS59511B1 (es)
SG (2)	SG11201407028WA (es)
SI (1)	SI2844292T1 (es)
SM (1)	SMT201900639T1 (es)
TW (3)	TWI589588B (es)
UA (1)	UA118336C2 (es)
UY (1)	UY34774A (es)
WO (1)	WO2013165894A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8961967B2 (en)	2009-11-30	2015-02-24	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
US10053513B2 (en)	2009-11-30	2018-08-21	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
US9090694B2 (en) *	2012-04-30	2015-07-28	Janssen Biotech, Inc.	ST2L antibody antagonists
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar)	2013-03-13	2020-07-05	Regeneron Pharma	الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2968454B1 (en)	2013-03-15	2019-02-13	Regeneron Pharmaceuticals, Inc.	Il-33 antagonists and uses thereof
ES2866935T3 (es)	2014-01-10	2021-10-20	Anaptysbio Inc	Anticuerpos dirigidos contra interleucina-33 (IL-33)
WO2015164354A1 (en)	2014-04-21	2015-10-29	The Childen's Hospital Of Philadelphia	Compositions and methods for treating cytokine-related disorders
EP3157634B1 (en)	2014-06-23	2018-12-12	Bionomics, Inc.	Antibodies that bind lgr4
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
JP7231326B2 (ja)	2014-11-10	2023-03-01	ジェネンテック，インコーポレイテッド	Ｉｌ－３３媒介性障害のための治療及び診断方法
EP3265493B1 (en)	2015-03-02	2024-01-10	180 Therapeutics LP	Method of treating a localized fibrotic disorder using an il-33 antagonist
JP7114460B2 (ja) *	2015-06-26	2022-08-08	サノフィ・バイオテクノロジー	モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
US20190016795A1 (en) *	2016-01-14	2019-01-17	Anaptysbio, Inc.	Inhibition of allergic reaction using an il-33 inhibitor
EP3241845A1 (en)	2016-05-06	2017-11-08	MAB Discovery GmbH	Humanized anti-il-1r3 antibodies
EP3570865A4 (en) *	2016-09-02	2020-05-20	180 Therapeutics LP	METHOD FOR TREATING A LOCALIZED FIBROTIC DISEASE USING A BISPECIFIC IL-33 / TNF ANTIBODY
EP3506920A4 (en) *	2016-09-02	2020-05-27	180 Therapeutics LP	METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY
JOP20190093A1 (ar)	2016-10-28	2019-04-25	Lilly Co Eli	أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh)	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
EP3601346A1 (en) *	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
MX2019012171A (es)	2017-04-13	2019-11-25	Regeneron Pharma	Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
EP3401332A1 (en)	2017-05-08	2018-11-14	MAB Discovery GmbH	Anti-il-1r3 antibodies for use in inflammatory conditions
MX2020006119A (es)	2017-12-21	2020-08-24	Hoffmann La Roche	Anticuerpos de union a hla-a2/wt1.
KR20220098056A (ko)	2018-02-09	2022-07-08	제넨테크, 인크.	비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
IL307286B2 (en)	2018-04-11	2026-03-01	Regeneron Pharma	Methods and reagents for IL-33 quantification
AU2019369498A1 (en) *	2018-10-31	2021-05-20	Delinia, Inc.	Multivalent regulatory T cell modulators
KR102353568B1 (ko)	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) *	2019-06-14	2019-09-03	迈威(上海)生物科技有限公司	用于测定人il-33/st2通路抑制剂的生物学活性的方法
IL292442A (en)	2019-11-04	2022-06-01	Medimmune Ltd	Anti-il-33 therapeutic agent for the treatment of kidney disorders
WO2021089563A1 (en)	2019-11-04	2021-05-14	Medimmune Limited	Methods of using il-33 antagonists
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
US20230110203A1 (en)	2020-03-13	2023-04-13	Medimmune Limited	Therapeutic methods for the treatment of subjects with risk alelles in il33
EP4132972A1 (en)	2020-04-06	2023-02-15	MedImmune Limited	Treating acute respiratory distress syndrome with il-33 axis binding antagonists
CN121851171A (zh)	2020-05-12	2026-04-14	正大天晴药业集团股份有限公司	St2抗原结合蛋白
CN113501878B (zh) *	2021-02-03	2022-12-02	北京智仁美博生物科技有限公司	针对人tslp的多种抗体及其用途
AR125753A1 (es)	2021-05-04	2023-08-09	Agenus Inc	Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202322850A (zh) *	2021-08-05	2023-06-16	美商美國禮來大藥廠	抗體最佳化
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
AU2023223413A1 (en) *	2022-02-24	2024-10-10	Sinomab Bioscience Limited	Bispecific binding proteins against alarmins and uses thereof
CN115838425B (zh) *	2022-08-31	2024-06-18	首都医科大学	一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用
AR130550A1 (es)	2022-09-21	2024-12-18	Sanofi Biotechnology	Anticuerpo anti-il-1r3 humanizado y métodos de uso
CN119841936B (zh) *	2024-12-30	2025-09-30	中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心)	抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5869620A (en)	1986-09-02	1999-02-09	Enzon, Inc.	Multivalent antigen-binding proteins
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2156149T3 (es)	1992-12-04	2001-06-16	Medical Res Council	Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO1995015388A1 (en)	1993-12-03	1995-06-08	Medical Research Council	Recombinant binding proteins and peptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
BR9606706A (pt)	1995-10-16	1999-04-06	Unilever Nv	Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6103529A (en)	1996-10-10	2000-08-15	Life Technologies, Inc.	Animal cell culture media comprising peptides derived from rice
GB9727172D0 (en)	1997-12-24	1998-02-25	Univ Glasgow	Reagents specific for st2l and uses therefor
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
GB9911569D0 (en)	1999-05-18	1999-07-21	Oxford Biomedica Ltd	Antibodies
US6323334B1 (en) *	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en)	2000-03-21	2001-10-03	Takao Arai	Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
US7083784B2 (en)	2000-12-12	2006-08-01	Medimmune, Inc.	Molecules with extended half-lives, compositions and uses thereof
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en)	2002-05-07	2003-11-18	The United States Of America As Represented By The United States Department Of Energy	Pump station for radioactive waste water
JP4794301B2 (ja)	2003-06-11	2011-10-19	中外製薬株式会社	抗体の製造方法
US20090215895A1 (en) *	2004-01-30	2009-08-27	Peplin Biolipids Pty Ltd	Therapeutic and carrier molecules
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2587627A1 (en)	2004-11-15	2006-05-26	Eli Lilly And Company	Desacyl ghrelin antibodies and therapeutic uses thereof
AU2006232287B2 (en)	2005-03-31	2011-10-06	Chugai Seiyaku Kabushiki Kaisha	Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt)	2006-03-24	2013-01-24	Merck Patent Gmbh	Domínios proteicos heterodiméricos modificados
JP2009541275A (ja)	2006-06-22	2009-11-26	ノボ・ノルデイスク・エー／エス	二重特異性抗体の生産
US7560530B1 (en)	2006-07-20	2009-07-14	Schering Corporation	IL-33 receptor
AR064801A1 (es)	2006-08-18	2009-04-29	Xoma Technology Ltd	Anticuerpo especifico prlr (receptor de prolactina) y sus usos
ES2593484T3 (es)	2007-03-29	2016-12-09	Genmab A/S	Anticuerpos biespecíficos y métodos de producción de los mismos
WO2008144610A1 (en) *	2007-05-18	2008-11-27	Medimmune, Llc	Il-33 in inflammatory disease
US8748356B2 (en)	2007-10-19	2014-06-10	Janssen Biotech, Inc.	Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en)	2007-12-19	2009-07-09	Centocor Ortho Biotech Inc.	Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
JP6157046B2 (ja)	2008-01-07	2017-07-05	アムジェンインコーポレイテッド	静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
US8817596B2 (en)	2009-01-09	2014-08-26	Futurewei Technologies, Inc.	Protecting ingress and egress of a label switched path
US7879978B2 (en) *	2009-03-31	2011-02-01	Centocor Ortho Biotech, Inc.	Macaca fascicularis ST2L
WO2010129304A2 (en)	2009-04-27	2010-11-11	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US8961967B2 (en) *	2009-11-30	2015-02-24	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
US20110206672A1 (en)	2010-02-25	2011-08-25	Melvyn Little	Antigen-Binding Molecule And Uses Thereof
HUE036157T2 (hu)	2010-03-30	2018-06-28	Janssen Biotech Inc	Humanizált IL-25 ellenanyagok
CN106620692B (zh)	2010-04-09	2021-04-09	重症监护诊断股份有限公司	可溶性人st-2抗体和分析法
HRP20241208T1 (hr)	2010-04-20	2024-11-22	Genmab A/S	Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en)	2010-05-14	2016-12-27	Rinat Neuroscience Corp.	Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en)	2010-08-20	2012-02-22	Leadartis, S.L.	Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2757857T3 (es)	2010-09-27	2020-04-30	Janssen Biotech Inc	Anticuerpos de unión a colágeno II humano
ES2758994T3 (es)	2010-11-05	2020-05-07	Zymeworks Inc	Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
EP2678358B1 (en)	2011-02-23	2015-07-22	F.Hoffmann-La Roche Ag	Antibodies against human il33r and uses thereof
US9090694B2 (en) *	2012-04-30	2015-07-28	Janssen Biotech, Inc.	ST2L antibody antagonists
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2

2013
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en not_active Ceased
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko not_active Expired - Fee Related
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-29 SM SM20190639T patent/SMT201900639T1/it unknown
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active Withdrawn
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
2015
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown

Also Published As

Publication number	Publication date
EP2844292A4 (en)	2016-05-25
JP6622274B2 (ja)	2019-12-18
JP2018064560A (ja)	2018-04-26
CN104411333B (zh)	2017-04-26
SG10201608525SA (en)	2016-12-29
NZ729913A (en)	2018-07-27
MX358134B (es)	2018-08-06
PH12018501839A1 (en)	2020-09-14
BR112014027165A2 (pt)	2017-07-18
AU2017202610B2 (en)	2019-06-13
TW201345923A (zh)	2013-11-16
WO2013165894A3 (en)	2014-03-27
IL254569A0 (en)	2017-11-30
US9090694B2 (en)	2015-07-28
CN104411333A (zh)	2015-03-11
TWI687440B (zh)	2020-03-11
PE20150641A1 (es)	2015-05-11
AR090909A1 (es)	2014-12-17
WO2013165894A2 (en)	2013-11-07
EP2844292B1 (en)	2019-08-21
EA201891264A2 (ru)	2018-11-30
LT2844292T (lt)	2019-11-25
US20130336980A1 (en)	2013-12-19
CR20140488A (es)	2015-01-12
RS59511B1 (sr)	2019-12-31
US10450377B2 (en)	2019-10-22
US20170066831A1 (en)	2017-03-09
DK2844292T3 (da)	2019-10-21
NI201400125A (es)	2016-11-30
NZ702136A (en)	2017-03-31
HRP20191884T1 (hr)	2020-02-07
TWI700299B (zh)	2020-08-01
CO7240389A2 (es)	2015-04-17
IL235401B (en)	2020-10-29
TW201730216A (zh)	2017-09-01
JP2019162136A (ja)	2019-09-26
EA201891264A3 (ru)	2019-02-28
US9951137B2 (en)	2018-04-24
EA031047B1 (ru)	2018-11-30
MX2018009430A (es)	2020-09-02
US9212227B2 (en)	2015-12-15
TWI589588B (zh)	2017-07-01
AU2013256645A1 (en)	2014-11-13
KR20150008152A (ko)	2015-01-21
CY1122308T1 (el)	2021-01-27
PH12014502435A1 (en)	2015-01-12
NZ740221A (en)	2019-11-29
CA2871948C (en)	2020-09-08
AU2017202610A1 (en)	2017-05-11
SG11201407028WA (en)	2015-01-29
PT2844292T (pt)	2019-11-26
ES2755094T3 (es)	2020-04-21
UA118336C2 (uk)	2019-01-10
TW202019969A (zh)	2020-06-01
IL254569B (en)	2020-10-29
MX2014013200A (es)	2014-12-08
US20190062439A1 (en)	2019-02-28
JP2015516817A (ja)	2015-06-18
HK1208182A1 (en)	2016-02-26
SI2844292T1 (sl)	2020-02-28
AU2017202610B9 (en)	2019-06-20
KR102147140B1 (ko)	2020-08-25
ECSP14025178A (es)	2015-08-31
SMT201900639T1 (it)	2020-01-14
MY166062A (en)	2018-05-22
AU2013256645B2 (en)	2017-06-08
JP6283354B2 (ja)	2018-02-21
EP3597219A1 (en)	2020-01-22
IL235401A0 (en)	2014-12-31
EA201491996A1 (ru)	2015-04-30
KR20200037886A (ko)	2020-04-09
PL2844292T3 (pl)	2020-03-31
CA2871948A1 (en)	2013-11-07
EP2844292A2 (en)	2015-03-11
UY34774A (es)	2013-11-29
US20130287777A1 (en)	2013-10-31
CN107098973A (zh)	2017-08-29
HUE045864T2 (hu)	2020-01-28

Publication	Publication Date	Title
CL2014002955A1 (es)	2015-01-16	Antagonista anticuerpo que se une a st2l y métodos de uso
FR24C1019I2 (fr)	2025-03-28	Anticorps anti-fcrn
FR21C1061I2 (fr)	2022-11-18	Anticorps anti-angptl3 et utilisations de ceux-ci
IL272831A (en)	2020-04-30	Meditopes and meditope-binding antibodies and uses thereof
CL2014003140A1 (es)	2015-02-27	Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
IL263320A (en)	2018-12-31	Anti-hemagglutinin antibodies and methods of use
CL2014002086A1 (es)	2015-02-27	Anticuerpos cd47 y métodos de uso los mismos
CL2016001556A1 (es)	2017-02-03	Anticuerpos anti-cd3 y métodos de uso
CO7020870A2 (es)	2014-08-11	Anticuerpos anti-htra1 y métodos de uso
BR112014032193A2 (pt)	2017-06-27	métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
PT2922875T (pt)	2017-05-31	Anticorpos anti-ceacam5 e suas utilizações
CL2015000582A1 (es)	2015-11-06	Anticuerpos anti-mcam y métodos asociados de uso
CR20150618A (es)	2016-02-08	Anticuerpos receptores de antitransferina y métodos de uso
EP2922874A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES
CR20150329A (es)	2015-08-24	Inmunoglobulinas heterodiméricas
EP2803662A4 (en)	2015-06-03	P2X4 Receptor Antagonists
IL236874B (en)	2019-08-29	Anti-kit antibodies and uses thereof
PL2731677T3 (pl)	2018-08-31	Przeciwciała wiążące się z OX40 i ich zastosowania
DK3593814T3 (da)	2026-04-27	Antistofformulering
DK2890397T3 (da)	2019-08-05	Antiprolactinreceptor-antistofformulering
EP2788377A4 (en)	2015-11-18	HER3 ANTIBODIES AND USES THEREOF
EP2837685A4 (en)	2016-02-24	ANTI-FGFR2 ANTIBODY
BR112014012590A2 (pt)	2017-06-20	anticorpos anti-cd98 e métodos de uso dos mesmos
BR112014002716A2 (pt)	2017-06-13	anticorpos anti-poliubiquitina e métodos de uso